Bharat Book Bureau

Wouldn’t it be great if you could answer these 3 questions everytime?, Will a drug be successful?, Will a drug make any money?, Is it worth investing in a drugs’ further development?, In these days of thin pipelines and revenues consolidating into a few products there is high pressure your company’s product managers to be sure that their next product, if not a blockbuster, is at least a winner. However, you will be fully aware that through Pharmacoeconomics, we can go some way to predict the future success of your drug!

But questions still remain

Are Pharmacoeconomics any good?
Do Pharmacoeconomics work?
it’s’s brand new report, answers these questions for you. This new report examines the link between this new developmental tool, the financial success of drug and how decision makers are increasingly using Pharmacoeconomics to make their drug purchases - are you using Pharmacoeconomics successfully?

Currently there are 4 economic factors in a pharmacoeconomic evaluation :

Cost minimisation
Cost effectiveness analysis (CEA)
Cost benefit analysis (CBA)
Cost utility analysis (CUA)
it’s’s Pharmacoeconomics and Success in the Marketplace report, examines these steps and points out their usefulness in a drugs’ commercial viability and market positioning.

The report also tackles crucial issues such as :

Formulary decisions
The current effective structure of Pharmacoeconomics
Data problems in implementing and succeeding in Pharmacoeconomics
The influence of Pharmacoeconomics in the pharmaceutical R&D sector
Global Pharmacoeconomic practice from the major industry players

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44655
_______________________________________________________________

Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 13.0% to 2009.it’s’s latest report, ” The Global Ophthalmic Pharmaceutical Market 2004-2009 ” , explains just how this market will experience growth over the medium term future.

The world market is currently valued at $7.25bn and revenues are forecasts to rise to over $14bn in 2009. Do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what stratergies can be used to maxmise profits from the drivers and restraints? Ensure your organisation is successful in this market by reserving your copy of it’s’s report today.

According to the findings of the new 170+page report, it’s reveals that Glaucoma therapies are set to dominate the market over the forecast period (2002-2009), accounting for almost 40% of market revenues by 2009. Indeed, 2004 saw the first blockbuster drug of the market, used to treat glaucoma.

Find out who are the major companies involved in the ophthalmic world market today and in the future. And what R&D opportunities exist for ‘new-comers’ to the ophthalmic pharmaceutical market.

In the process of providing a thorough evaluation of the market, the it’s Ophthalmics report focuses on the major therapeutic areas of the market:
Glaucoma
AMD
Ocular Allergies
Dry Eye Syndrome
Ocular Infections
Ocular Inflammation
Do you know what the market values of these major therapeutic areas of the ophthalmic world market are?

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC ophthalmic drugs by disease and product type. The study also assess’s the challenges faced by ophthalmic companies, and what exciting market opportunites exist in this up- and-coming therapeutic area.

Why You Must Buy This Report?

This report features over 50 tables, 30 graphs and charts, news, insights, the latest developments and an in depth survey of the ophthalmics market with up-to-date analysis. This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company ‘the edge’ on your competitiors. You can not afford to be without this latest report from it’s.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44656
_______________________________________________________________

According to indepth analysis from Dr Ray Scraggs, Senior Pharmaceutical Industry Analyst with It the total value of the world market for antifungal medication, topical as well as systemic, was worth in 2003 nearly $6 billion. The report entitles The World Market for Antifungal Therapies 2004-2009 divides the total market into:

Systemic :

Topical OTC and Prescription
This is one of the few reports of this type on the market that attempts an analyses of both the systemic and topical markets.

Further the systemic market is subdivided into analyses that includes :
Azoles
Polyenes
Pyrimidines
Allylamines
Echinodians

According to Dr Scraggs the total market will see a growth rate decline with an average growth rate (AAGR) from 2002-2009 of only 39.1 per cent, revenues by 2009 will be approaching $8 billion. Systemic antifungals, not surprisingly dominate this market with a 60 per cent market share. This is a market you must become successful in.  There is a significant unmet need in this market because the present portfolio of treatments interact unfavourably with other medications, have resistance problems, low spectrum of activity, are fungistatic as opposed to fungicidal and are often toxic. The company that can arrive at a new class of drug that can overcome all these limitations will be guaranteed high profits.

Key Questions Answered in this Report :

Total revenues and growth rates for each market segment from 2002-2009
A list of the important drivers and restraints
Incisive market predictions for each segment and individual drug type
A market share analysis of each segment
New products and new developments
A review of the latest innovations in antifungal vaccine discovery
Analysis of market trends

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44659
_______________________________________________________________

The world vaccine market, once characterized by slow growth, has seen increased sales as a result of new paediatric vaccines and the burgeoning influenza vaccine markets in the U.S. and Europe. You should be taking advantage of this growth NOW!!. The adult market for vaccines is predicted to grow by 26.3 per cent in 2004, but what will it be in 2007 - only It’s unique report can tell you today.

In 2003 the world vaccine market is valued at over $5 billion, shouldn’t you be claiming an increased share of this market immediately.

Paediatric vaccines still hold the largest share of the overall market, but influenza and hepatitis vaccine sales have grown significantly over the past few years. Paediatric vaccines markets are growing at a slower rate than the adult market and you need to position your company correctly to ensure your continued success.

A large number of therapeutic vaccines under development prove to make the vaccine market an interesting and dynamic one over the next five years. Therapeutic vaccines are currently being tested against cancer and are approaching approval.

The Therapeutic and Prophylactic Vaccine Market 2003 provides in-depth analysis of the vaccine market, presents key findings that are driving the market, and contains up-to-date information regarding vital clinical trials, sales figures, and profiles of key vaccine companies.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44660
_______________________________________________________________

The combined value of the women’s reproductive health pharmaceutical market is currently over $20 billion. A positive growth rate of 8 per cent is expected per annum for the next five years, according to It Publishing of London. An expanded variety of contraceptive choices for women is driving growth, as is continued growth in the gonadotrophins class for infertility.

Negative press regarding the side effects associated with hormone replacement therapy (HRT) has slowed this market down slightly, leaving a vaccum of market share for other osteoporosis therapies. HRT will, however, rebound during the forecast period and re-achieve strong growth.

Women’s Reproductive Health 2004 is arranged to provide an overview of this complex market. Specific attention is given to the following areas:
Contraception
Infertility
Osteoporosis/Menopause
Analysis and financial forecasts in these markets take into account many factors including:
Consumer preference statistics
Product differentiation
New indications
Patent expirations
Generic competition
The Women’s Health Institute HRT Study
Emerging markets, eg. Japan
Detailed financial information and forecasting is also provided for each chapter including in-depth coverage of drugs in the infertility and osteoporosis drug markets such as:
Gonadotrophins
Bisphosphonates
Selective estrogen receptor modulators
GnRH Antagonists
Hormone replacement therapy
Detailed product differentiation and financial analysis is presented for the following contraceptive products:
Hormonal contraceptives
Intra-uterine devices
Transdermal patches
Depot contraceptives
Emergency contraception

Analysis includes the use of charts and graphs measuring product growth and trends within the women’s reproductive health marketplace. Company-specific information, including sales figures, drug pipeline status, and research and development trends is provided throughout the report. Five-year financial forecasts are also provided

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44661
_______________________________________________________________

In 2006, Teva Pharmaceutical Industries generated $8408m in net sales worldwide from both innovative branded and generic drugs, firmly establishing itself as a Top-20 international pharmaceutical company and leader in generics. That performance reflects rapid growth in recent years, as represented by a tripling in sales from $2519m in 2002. By 2010, total sales for Teva should reach $13.3bn. These are some of the findings from the “Teva Pharmaceutical Industries Market Forecasts 2007-2012″ report.

Report author Dr Gordon Low said: “With spectacular sales growth in recent quarters, Teva will raise its profile even higher in the global pharmaceutical sector. Growth will be particularly evident in branded generics and innovative products. In particular, there will be significant developments in NCE development and international business, including further launches of innovative therapeutic molecules later this decade and early in the next.” Stakeholders in the industry therefore cannot afford to ignore developments in Teva.

The purpose of this report is to examine the commercial prospects for Teva Pharmaceutical Industries in the global healthcare market. Teva is already competing well there, especially in key market segments and developing geographical markets. Its profile as a leading generics and innovation-driven pharmaceutical company will continue to rise. Teva Pharmaceutical Industries 2007-2012, critically examines that company through comprehensive research, market forecasting and qualitative analyses.

Teva’s leading product is Copaxone, for multiple sclerosis, which generated $1414m during 2006. Other revenues are generated from a wide portfolio of generic pharmaceutical products and another innovative drug, Azilect, a treatment for Parkinson’s disease. Teva also produces and markets active pharmaceutical ingredients (APIs) for the industry worldwide.

After its acquisition of generics rival -Ivax Corporation - in a deal finalised in early 2006, Teva achieved overall leadership of the global generics market. Teva clearly has a robust corporate strategy that should serve it well for years to come, driving strong growth and further innovation. Teva is therefore one of the most exciting and dynamic companies in the global pharmaceutical industry. Consequently, participants in the global market should pay close attention to developments in Teva.

Teva Pharmaceutical Industries 2007-2012 examines that company critically, through comprehensive research and analysis. Importantly, Its discusses Teva in the context of the wider pharmaceutical market. This market-based research involved a detailed study of commercial documents, databases, company reports and relevant news. Importantly, applied techniques such as financial forecasting, SWOT analysis and qualitative projections.

In particular, Teva Pharmaceutical Industries 2007-2012 concentrates on the following essential aspects of that company:

Detailed analysis of Teva’s divisions and the performance of its products
Sales forecasts for all Teva’s divisions and the overall group
Sales forecasts for Teva’s innovative drugs - Copaxone and Azilect
Discussions of issues affecting the relevant market segments
Competitor analysis
Drivers and opportunities for Teva
Restraints and threats facing the company
Discussions of corporate strategy in the context of the market
Strategic alliances and licensing
International operations
Pipeline developments and their implications for the future

Leading generics companies such as Teva have established a new paradigm in the generics sector: that of developing innovative drugs. Other international generics companies are in a race to catch up with Teva, the world’s leader in generics and a Top-20 pharmaceutical company in its own right. Teva has already achieved success with its leading innovative product Copaxone. It predicts that Teva’s sales revenues will continue to rise strongly, as it harnesses opportunities in the expanding generics market and makes further progress as a global discovery-led company.

Unique benefits to you when you order this report

Full searchable report when you buy the company or corporate editions
Immediate access through our exclusive Reading Room
You can access your report whichever country you are in without using harddrive space
Primary research throughout. You will not find this information anywhere else
Report stored in your reading room for ever
Copies can be printed off for offline reading
Packed with charts, analysis, figures, graphs and tables

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=46978
_______________________________________________________________

“By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, researcher has found”.  For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities.

This high-level management report examines the commercial prospects for anti-obesity prescription drugs in the global healthcare market. With obesity now the most common nutritional disorder in western industrialised countries, is your company’s pipeline showing the potential blockbuster the market offers? Obesity in the US and Europe has already reached high levels, with obesity being described as an epidemic and a “public health time-bomb”. Government funding continues to increase, especially in the most seriously affected areas – the US and Europe.

The U.S. health panel’s rejection of Sanofi-Aventis’ obesity drug Zimulti however has cast a shadow over other experimental products in the same class while offering a stark reminder of challenges facing the development of weight-loss medications. The Food and Drug Administration advisory panel on Wednesday unanimously recommended Zimulti not be approved because of concerns it may increase suicidal thinking and depression. The FDA is expected to make a final decision by July 26.

Obesity is an major risk factor for serious, chronic diseases such as type 2 diabetes, heart disease, stroke and certain cancers. In addition, obese people are more likely to suffer from psychological problems and a poorer quality of life in general. The increase in obesity during recent decades involves a complex interplay of environmental, social, economic, genetic and behavioural factors. Its most prominent causes include unhealthy modern diets – high in sugars and fats - and reduced physical activity.

New drugs in the field have the potential to treat a range of conditions associated with metabolic syndrome, with high potential revenues and life cycle benefits. It concludes that the commercial opportunities for anti-obesity medications are significant, predicting multi-billion revenues for the anti-obesity segment by early next decade. Nevertheless, there are many hurdles that market participants will have to overcome, particularly convincing healthcare authorities and practitioners that the drugs have adequate efficacy, safety and cost-effectiveness.

Anti-Obesity Treatments 2007-2012, examines the market for anti-obesity drugs critically, through comprehensive primary and secondary research. In addition to consultation with experts in medical practice, academia and industry, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, It also applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=52065
_______________________________________________________________

Increasingly the large pharmaceutical companies are pumping money and ambition into the DNA/RNA therapy market. Whether its through forming collaboration/licensing agreements, or acquiring smaller companies they can see the financial opportunities. In particular the large pharmaceutical companies Pfizer, Sanofi-Aventis, Eli Lilly & Company and Merck & Co all have substantial investment in the RNA/DNA therapy products market. With Merck & Co in particularly showing its faith in the future potential of this market by taking the gamble of acquiring the specialist RNAi company Sirna, towards the end of 2006.

This interest reflects the advances being made in this sector and implies that it is eventually on the verge of success. The investment of these larger companies makes that success both more likely to occur and more likely to occur quickly. Are you missing out? Have you positioned your company correctly to benefit from these opportunities? The vast potential of RNA/DNA therapies to treat the cause of disease across many therapeutic areas is set to be realized. Be part of that now.

This brand new high-level management report focuses on the commercial and strategic opportunities within the human genome project. It examines the companies utilizing novel molecular biological techniques to try to exploit this knowledge to produce RNA/DNA products. The genetic characterisation of many viruses is also leading to DNA and RNA products being used to treat infectious disease, a therapeutic area for which traditional drug development is difficult, as with the recent announcement regarding AIDS research.

It has been identified that 68 companies are actively involved in this field, 35 of these companies are primarily focused on the development of RNA/DNA therapy products and 33 companies are involved in collaborations. This represents a substantial investment in the future of the RNA/DNA therapy products market and over the forecast period It believes this investment will begin to pay off. There are 2 RNA/DNA therapy products due to submit licence applications in 2007, with a further 67 products in clinical trials and a further 45 products in pre-clinical development. Of these products It has identified 14 that it believes have the greatest potential both to be launched before 2012 and to make a contribution to this market. This would result in a substantial increase in the RNA/DNA therapy product market over the forecast period and imply that this sector is eventually achieving some of its anticipated potential.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=52066
_______________________________________________________________

In 2007, we believe the anti-smoking market to be worth $1.7 billion. This is a growth of 37% from the year before. This latest report, Global Smoking Cessation Market Analysis & Forecasts - preparing for the first blockbuster, explains just how this market will experience growth over the medium term future. Also do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what strategies can be used to maximize profits from the drivers and restraints.

In this report each one of these disease areas is examined in terms of market growth and revenue. Plus we examine how current and new drug treatments will take hold in each market, plus which companies will succeed in each market.

According to the findings of this new report, it reveals that the nicotine vaccine market will generate over $1 billion plus that Pfizer’s nicotinic receptor will be the markets first blockbuster drug.  Can any of these drugs compete with the OTC market leaders? How will GSK’s Zyban be effected with direct competition from Chantix/ Champix? However are there any others which can compete with this for market share or beat its dominance? This report answers that question, with an analysis of other players in the market.

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC smoking cessation drugs by product type. The study also assess’ the challenges faced by anti-smoking companies, and what exciting market opportunities exist in this up- and-coming therapeutic area.

For more information, kindly visit :

In this report each one of these disease areas is examined in terms of market growth and revenue. Plus we examine how current and new drug treatments will take hold in each market, plus which companies will succeed in each market.

According to the findings of this new report, it reveals that the nicotine vaccine market will generate over $1 billion plus that Pfizer’s nicotinic receptor will be the markets first blockbuster drug.

Can any of these drugs compete with the OTC market leaders? How will GSK’s Zyban be effected with direct competition from Chantix/ Champix? However are there any others which can compete with this for market share or beat its dominance? This report answers that question, with an analysis of other players in the market.

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC smoking cessation drugs by product type. The study also assess’ the challenges faced by anti-smoking companies, and what exciting market opportunities exist in this up- and-coming therapeutic area.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=52067
_______________________________________________________________

 Service Delivery Platforms (SDPs) generally simplify architectures, eliminate the need for costly and inflexible vertical structures and also significantly reduce the need for specialized skills in the service development field. Through the use of SDPs processes are automated and service deployment time is reduced. This suggests that the average revenue per user (ARPU) for each new service and application introduced by an operator can be increased by approximately 2.5 times. That is the simple fact that can ensure your company increases profitability and increases it now.

SOA (Service Oriented Architecture) adherent SDPs are particularly important enabling providers to future proof their investment in SDP platforms Scalable SOA architecture will be able to pinpoint the overloaded application enablers within the SDP as it will be possible to add extra capacity through the upgrade of hardware only.

Operators are able to rapidly and cost-effectively deploy a variety of new applications and services through the use of SDPs. These applications will be primarily related to the areas of FMC, presence, location, gaming and advertising. Carriers can mix services from the aforementioned areas that will be aimed at specific segments of the market. This is of paramount significance since as the price of triple-play offerings are dropping and new innovative applications can increase their revenue. Also, SDPs can assist fixed, wireless and cable carriers to avoid becoming dumb pipes by playing a more active role in the development of the many new applications and services that will be created in the future.

This report Service Delivery Platforms & Service Orientated Architecture Report 2007-2012 highlights the role of SDPs in today’s telecom markets, and clarifies for you operator’s deployment strategies. Clear opportunities for IMS and converged services are offered to you within this report along with analysis of the companies most likely to succeed in the industry.

The report provides forecasts for revenue generation from these services and describes the key drivers to successful future of SDPs, SOA and possible applications. By buying this report, you will be ideally placed to profit from IMS development. We urge you to order it TODAY.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=57133
_______________________________________________________________